Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Raleigh, North Carolina 27607


The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy.


For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - ECOG Status: PS 0-1 & PS 2 - Subjects with histologically or cytologically-documented SqNSCLC - Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen - Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria - Subjects with treated or asymptomatic CNS metastases - Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration - Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab - Males and Females, ages 18 or older Exclusion Criteria: - Subjects with untreated, symptomatic CNS metastases - Subjects with carcinomatous meningitis - Subjects with active, known or suspected autoimmune disease. - Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.



Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb

Backup Contact:


Location Contact:

Raleigh, North Carolina 27607
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.